BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 25475897)

  • 1. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
    Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
    Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
    Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
    Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.
    Knox AJ; Scaling AL; Pinto MP; Bliesner BS; Haughian JM; Abdel-Hafiz HA; Horwitz KB
    Breast Cancer Res; 2014 Aug; 16(4):418. PubMed ID: 25116921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
    Sihto H; Lundin J; Lundin M; Lehtimäki T; Ristimäki A; Holli K; Sailas L; Kataja V; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
    Breast Cancer Res; 2011 Sep; 13(5):R87. PubMed ID: 21914172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
    Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
    J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
    Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
    Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.
    Haughian JM; Pinto MP; Harrell JC; Bliesner BS; Joensuu KM; Dye WW; Sartorius CA; Tan AC; Heikkilä P; Perou CM; Horwitz KB
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2742-7. PubMed ID: 21969591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
    Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
    Harrell JC; Dye WW; Allred DC; Jedlicka P; Spoelstra NS; Sartorius CA; Horwitz KB
    Cancer Res; 2006 Sep; 66(18):9308-15. PubMed ID: 16982776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
    Sartorius CA; Harvell DM; Shen T; Horwitz KB
    Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
    Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of an estrogen receptor-regulated gene by first generation progestins requires both the progesterone receptor and estrogen receptor alpha.
    Perkins MS; Louw-du Toit R; Jackson H; Simons M; Africander D
    Front Endocrinol (Lausanne); 2022; 13():959396. PubMed ID: 36187129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III.
    Finlay-Schultz J; Gillen AE; Brechbuhl HM; Ivie JJ; Matthews SB; Jacobsen BM; Bentley DL; Kabos P; Sartorius CA
    Cancer Res; 2017 Sep; 77(18):4934-4946. PubMed ID: 28729413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.